Refine by
Critically Ill Covid 19 Patients Articles & Analysis
92 news found
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
BIOtechNOW featured IVS’s participating BIO Innovation Zone Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech ...
Fresenius Kabi has been selected to exhibit the Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17, 2022, in Dallas. The annual Innovative Technology Exchange offers selected suppliers the opportunity to demonstrate their technologies to ...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. ...
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patients Company to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography (“PET”) hypoxia imaging methodology with data expected ...
ByCervoMed
Sensor advancements are driving innovation in both wearable devices and surgical devices. Speakers at the MD&M West 2020 conference explore several developments. The role of sensors in medical devices is becoming increasingly more important, especially when it comes to developing new technologies such as wearable devices that can diagnose and transmit information for long periods of ...
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. Prof. Thomas Rand, MD from the Klinik Floridsdorf Vienna, Austria presented the initial ...
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the SeptiCyte® RAPID (developed in collaboration with Immunexpress) and one on the Idylla™ SARS-CoV-2 Test (CE-IVD) and Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD), ...
Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science companies across multiple use cases. The multi-year agreement will enable linking and access to xCures de-identified data and Prognos healthcare data marketplace. “We are excited about combining ...
ByxCures
Amsel Medical Corp. today announced the appointment of Jeff Willis as Senior Director of Engineering to help drive the current product commercialization phase and implement the company’s strategy to address the demand for minimally invasive, simple and secure occlusion. “Jeff is an exceptionally focused engineer and executor,” said Amsel Medical CEO David Doster. “He ...
Following the announced closing of the acquisition of Ivenix and its advanced infusion pump technology, Fresenius Kabi now offers healthcare professionals a broad and expanding portfolio of advanced infusion pumps and solutions to meet health care needs across the continuum of care. Fresenius Kabi is the leading provider of IV pumps and solutions in Europe. The company is now investing to ...
Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive inflammation, organ failure and ...
I believe the benefits of our innovative blood purification technology will make a positive impact on the lives of treated patients throughout the region,” said Whittemore. Dr. Christian Steiner, Executive Vice President, Sales and Marketing of CytoSorbents stated, “As we establish a direct sales team in the UK and Ireland, we are excited to work more closely with ...
SERB and BTG Specialty Pharmaceuticals are pleased to announce that Thomas Kolaras has been named the group’s new Chief Commercial Officer for its US business. Thomas is an accomplished commercial leader with more than 25 years of US and global experience across large and mid-sized biopharmaceutical companies. His career includes a wide range of roles in marketing, sales, operations, ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive inflammation, organ failure and ...
SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US and Japan. Financial terms of the transaction were not disclosed. Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by ...
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since ...
Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer. The combination of novel molecular imaging agents and advanced visualisation ...